Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBIO NASDAQ:CDXS NASDAQ:FBIO NASDAQ:VNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$14.24+4.0%$13.62$10.83▼$63.00$267.64M1.5991,506 shs137,894 shsCDXSCodexis$2.42$2.82$1.90▼$6.08$218.45M2.541.40 million shs722,273 shsFBIOFortress Biotech$3.71+30.6%$2.10$1.33▼$3.72$84.50M1.61666,916 shs6.38 million shsVNDAVanda Pharmaceuticals$4.61-0.6%$4.63$3.81▼$5.55$274.17M0.74443,574 shs334,742 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma+3.48%-3.25%+18.02%-98.22%-98.22%CDXSCodexis+0.41%-11.03%-17.41%+2.11%-14.49%FBIOFortress Biotech-3.73%+17.36%+49.08%+42.00%+51.87%VNDAVanda Pharmaceuticals-1.69%-1.28%+10.21%+0.65%-8.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$14.24+4.0%$13.62$10.83▼$63.00$267.64M1.5991,506 shs137,894 shsCDXSCodexis$2.42$2.82$1.90▼$6.08$218.45M2.541.40 million shs722,273 shsFBIOFortress Biotech$3.71+30.6%$2.10$1.33▼$3.72$84.50M1.61666,916 shs6.38 million shsVNDAVanda Pharmaceuticals$4.61-0.6%$4.63$3.81▼$5.55$274.17M0.74443,574 shs334,742 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma+3.48%-3.25%+18.02%-98.22%-98.22%CDXSCodexis+0.41%-11.03%-17.41%+2.11%-14.49%FBIOFortress Biotech-3.73%+17.36%+49.08%+42.00%+51.87%VNDAVanda Pharmaceuticals-1.69%-1.28%+10.21%+0.65%-8.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCrescent Biopharma 3.33Buy$25.6079.78% UpsideCDXSCodexis 2.50Moderate Buy$11.00354.55% UpsideFBIOFortress Biotech 3.00Buy$16.50344.74% UpsideVNDAVanda Pharmaceuticals 3.50Strong Buy$16.50257.92% UpsideCurrent Analyst Ratings BreakdownLatest FBIO, CBIO, VNDA, and CDXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025CBIOCrescent BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/25/2025CBIOCrescent BiopharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.008/21/2025FBIOFortress BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $17.008/21/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/11/2025CBIOCrescent BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.007/14/2025CBIOCrescent BiopharmaWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$27.006/25/2025CBIOCrescent BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.006/20/2025CBIOCrescent BiopharmaTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/18/2025CBIOCrescent BiopharmaLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$22.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCrescent Biopharma$10K27,839.20N/AN/A$8.24 per share1.73CDXSCodexis$59.35M3.68N/AN/A$0.82 per share2.95FBIOFortress Biotech$57.67M1.91N/AN/A($0.06) per share-61.83VNDAVanda Pharmaceuticals$198.77M1.37N/AN/A$9.24 per share0.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCrescent Biopharma-$37.88M-$34.93N/AN/AN/AN/A-106.06%-86.60%N/ACDXSCodexis-$65.28M-$0.83N/AN/AN/A-113.67%-105.83%-46.06%10/30/2025 (Estimated)FBIOFortress Biotech-$46M-$1.05N/AN/AN/A-24.84%-301.81%-27.48%11/13/2025 (Estimated)VNDAVanda Pharmaceuticals-$18.90M-$1.13N/AN/AN/A-32.90%-12.89%-10.47%11/5/2025 (Estimated)Latest FBIO, CBIO, VNDA, and CDXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FBIOFortress Biotech-$0.31-$0.46-$0.15$0.45$14.53 million$16.41 million8/13/2025Q2 2025CDXSCodexis-$0.17-$0.16+$0.01-$0.16$14.18 million$15.33 million7/31/2025Q2 2025VNDAVanda Pharmaceuticals-$0.34-$0.46-$0.12-$0.46$54.77 million$52.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCrescent BiopharmaN/AN/AN/AN/AN/ACDXSCodexisN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCrescent BiopharmaN/A9.219.21CDXSCodexis0.715.825.70FBIOFortress Biotech1.341.921.70VNDAVanda PharmaceuticalsN/A3.253.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCrescent Biopharma75.19%CDXSCodexis78.54%FBIOFortress Biotech96.51%VNDAVanda Pharmaceuticals88.14%Insider OwnershipCompanyInsider OwnershipCBIOCrescent Biopharma4.00%CDXSCodexis1.90%FBIOFortress Biotech27.90%VNDAVanda Pharmaceuticals10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCrescent Biopharma5019.55 million18.77 millionNo DataCDXSCodexis25090.27 million88.55 millionOptionableFBIOFortress Biotech17029.75 million21.45 millionOptionableVNDAVanda Pharmaceuticals29059.09 million53.18 millionOptionableFBIO, CBIO, VNDA, and CDXS HeadlinesRecent News About These CompaniesWellington Management Group LLP Cuts Stock Holdings in Vanda Pharmaceuticals Inc. $VNDASeptember 2 at 3:58 AM | marketbeat.comNuveen LLC Acquires Shares of 440,561 Vanda Pharmaceuticals Inc. $VNDASeptember 1, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $2.18 Million Stake in Vanda Pharmaceuticals Inc. $VNDASeptember 1, 2025 | marketbeat.comVanda: Next Phase Of Fanapt Growth Might Be With Bysanti AdvancementAugust 29, 2025 | seekingalpha.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia ...August 29, 2025 | finanznachrichten.deVanda Pharmaceuticals Announces Participation at September 2025 Investor ConferencesAugust 28, 2025 | prnewswire.comVanda Pharmaceuticals gets FDA orphan drug status for VGT-1849BAugust 28, 2025 | seekingalpha.comVanda Pharmaceuticals stock rises after FDA orphan drug designationAugust 28, 2025 | za.investing.comVanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia VeraAugust 28, 2025 | prnewswire.comVanda Pharmaceuticals treatment of polycythemia vera granted orphan designationAugust 27, 2025 | msn.comVanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at HC WainwrightAugust 23, 2025 | marketbeat.comVanda seeks FDA Commissioner review of Hetlioz generic rulingAugust 22, 2025 | msn.comVanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®August 21, 2025 | prnewswire.comVanda wins appeals court fight over FDA jet lag rulingAugust 19, 2025 | thepharmaletter.comTVanda Pharmaceuticals Shares Climb After Court Reverses FDA DecisionAugust 18, 2025 | msn.comVanda Pharmaceuticals shares rise after court overturns FDA denialAugust 18, 2025 | za.investing.comVanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-MarkAugust 18, 2025 | msn.comIn a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag DisorderAugust 18, 2025 | prnewswire.comHC Wainwright Issues Pessimistic Outlook for VNDA EarningsAugust 16, 2025 | marketbeat.comHC Wainwright Has Bearish Forecast for VNDA Q4 EarningsAugust 15, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $4.27 Million Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)August 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBIO, CBIO, VNDA, and CDXS Company DescriptionsCrescent Biopharma NASDAQ:CBIO$14.24 +0.55 (+4.02%) As of 04:00 PM EasternCrescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Codexis NASDAQ:CDXS$2.42 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.49 +0.07 (+2.89%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Fortress Biotech NASDAQ:FBIO$3.71 +0.87 (+30.63%) Closing price 04:00 PM EasternExtended Trading$3.94 +0.23 (+6.20%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Vanda Pharmaceuticals NASDAQ:VNDA$4.61 -0.03 (-0.65%) Closing price 04:00 PM EasternExtended Trading$4.59 -0.02 (-0.43%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon Share Price Has Plenty of Room Left to Fall Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Lockheed Martin: Is the Market Overlooking This Defensive Giant? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
